FDA cleared the Cleerly ISCHEMIA from Cleerly, Inc. on Oct 29, 2026 under K262839, a special 510(k). The device falls under product code QXZ, Adjunctive Epicardial Vascular Physiologic Status Indicator, regulated at 21 CFR 870.2200 as a Class 2 device. The review panel was Cardiovascular.

FDA logged the submission as received on Aug 11, 2026. The decision came 79 days later, inside the 90 FDA-day goal for a 510(k).

Cleerly, Inc. has 2 other decisions in the tracker over the last 12 months: K260588 (Cleerly LABS), K261210 (Cleerly Plaque).